title: Antithrombotic therapy following transcatheter aortic valve implantation: what challenge do we face?
abstract: The issue of stroke and bleeding events following transcatheter aortic valve implantation (TAVI) and its relation with antithrombotic regimens before, during and after the procedure is increasingly recognized as an important issue. While dedicated trials are ongoing, there is no clear evidence at present on the best antithrombotic regimen in the context of TAVI. In this article, we will go through the mechanisms involved in embolic and bleeding complications of TAVI, and we will discuss the key aspects of antithrombotic treatment in patients undergoing TAVI.
authors.affiliation: a Division of Cardiology-Ferrarotto Hospital , University of Catania , Catania , Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Barbanti
authors.affiliation: a Division of Cardiology-Ferrarotto Hospital , University of Catania , Catania , Italy.
authors.forename: Simona
authors.initials: S
authors.lastname: Gulino
authors.affiliation: a Division of Cardiology-Ferrarotto Hospital , University of Catania , Catania , Italy.|b ETNA Foundation , Catania , Italy.
authors.forename: Corrado
authors.initials: C
authors.lastname: Tamburino
authors.affiliation: a Division of Cardiology-Ferrarotto Hospital , University of Catania , Catania , Italy.
authors.forename: Davide
authors.initials: D
authors.lastname: Capodanno
mesh_terms: D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D020521:Stroke / Q000209:etiology; D065467:Transcatheter Aortic Valve Replacement / Q000009:adverse effects / Q000379:methods*
chemical_list: D005343:Fibrinolytic Agents
keywords: TAVI; anticoagulant therapy; antiplatelet therapy; aspirin; bivalirudin; bleeding; clopidogrel